TR199901468T2 - Alfa-2 adrenoseptör agonistleri olarak yararli guanidinil heterosikl bilesikleri. - Google Patents

Alfa-2 adrenoseptör agonistleri olarak yararli guanidinil heterosikl bilesikleri.

Info

Publication number
TR199901468T2
TR199901468T2 TR1999/01468T TR9901468T TR199901468T2 TR 199901468 T2 TR199901468 T2 TR 199901468T2 TR 1999/01468 T TR1999/01468 T TR 1999/01468T TR 9901468 T TR9901468 T TR 9901468T TR 199901468 T2 TR199901468 T2 TR 199901468T2
Authority
TR
Turkey
Prior art keywords
alpha
compounds useful
adrenoceptor agonists
heterocycle compounds
guanidinyl
Prior art date
Application number
TR1999/01468T
Other languages
English (en)
Inventor
Lee Cupps Thomas
Eva Bogdan Sophie
Todd Henry Raymond
James Sheldon Russell
Lee Seibel William
Joseph Ares Jeffrey
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of TR199901468T2 publication Critical patent/TR199901468T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Bu bulus Istemlerde açiklanan (I) yapisini haiz bilesiklere; bunlarin enantiomerleri, optik izomerleri, stereoizomerleri, diastereomerleri, totomerleri, ilave tuzlari, biyohidrolize edilebilir amitleri ve esterlerine ve bu yeni bilesikleri içeren farmasötik bilesimlere iliskindir. Bulus ayrica bu bilesiklerin alfa-2 adrenoseptörleri tarafindan degistirilmis bozukluklari önlemek veya tedavi etmek için kullanimina iliskindir.
TR1999/01468T 1996-11-25 1997-11-21 Alfa-2 adrenoseptör agonistleri olarak yararli guanidinil heterosikl bilesikleri. TR199901468T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3202396P 1996-11-25 1996-11-25

Publications (1)

Publication Number Publication Date
TR199901468T2 true TR199901468T2 (tr) 1999-10-21

Family

ID=21862692

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01468T TR199901468T2 (tr) 1996-11-25 1997-11-21 Alfa-2 adrenoseptör agonistleri olarak yararli guanidinil heterosikl bilesikleri.

Country Status (25)

Country Link
US (3) US6225331B1 (tr)
EP (1) EP0944604B1 (tr)
JP (1) JP2001506600A (tr)
KR (1) KR20000069131A (tr)
CN (1) CN1104422C (tr)
AR (1) AR009145A1 (tr)
AT (1) ATE286885T1 (tr)
AU (1) AU730369B2 (tr)
BR (1) BR9713536A (tr)
CA (1) CA2272640C (tr)
CO (1) CO4910148A1 (tr)
CZ (1) CZ184099A3 (tr)
DE (1) DE69732244T2 (tr)
ES (1) ES2236833T3 (tr)
HU (1) HUP0000312A3 (tr)
ID (1) ID23857A (tr)
IL (1) IL130077A0 (tr)
NO (1) NO313912B1 (tr)
NZ (1) NZ336010A (tr)
PE (1) PE16399A1 (tr)
RU (1) RU2194700C2 (tr)
SK (1) SK69799A3 (tr)
TR (1) TR199901468T2 (tr)
WO (1) WO1998023596A1 (tr)
ZA (1) ZA9710578B (tr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69732244T2 (de) 1996-11-25 2006-06-29 The Board Of Regents Of The University Of Nebraska, Lincoln Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
MXPA03001437A (es) * 2000-09-08 2005-06-03 Warner Lambert Co Prevencion de sinusitis aguda y crisis sinusal.
EP1767525A1 (en) * 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
EP1487474A4 (en) * 2002-02-25 2006-11-29 Chiron Corp INTRANASAL ADMINISTRATION OF MC4-R AGONISTS
DE60333937D1 (de) * 2002-05-23 2010-10-07 Novartis Vaccines & Diagnostic Substituierte quinazolinone verbindungen
KR20060018217A (ko) * 2003-05-23 2006-02-28 카이론 코포레이션 Ｍｃ4-ｒ 작용제로서 구아니디노-치환된 퀴나졸리논 화합물
RU2254855C2 (ru) * 2003-09-10 2005-06-27 Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" Противовирусное средство и способ его получения
EP1686996A4 (en) * 2003-11-19 2008-11-12 Novartis Vaccines & Diagnostic CHINAZOLINONE COMPOUNDS WITH REDUCED BIOAC CUMULATION
JP5833804B2 (ja) * 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
TWI417099B (zh) * 2007-03-23 2013-12-01 Neuraxon Inc 具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物
EP2220074A4 (en) * 2007-11-16 2012-01-04 Neuraxon Inc 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
GB0919889D0 (en) * 2009-11-13 2009-12-30 Biocopea Ltd Drug composition and its use in therapy
JP5959537B2 (ja) * 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
CN112047947A (zh) * 2020-10-13 2020-12-08 石药集团新诺威制药股份有限公司 一种茶碱的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU148414A1 (ru) * 1961-07-03 1961-11-30 Е.Н. Зильберман Способ получени имидазолов и оксазолов
US3908013A (en) 1970-09-17 1975-09-23 Armour Pharma Pharmaceutical aromatic guanidine compositions and methods of using same
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3947455A (en) 1974-04-15 1976-03-30 Armour Pharmaceutical Company 5'-(8'-Hydroxyquinolyl)guanidine compounds
US4000279A (en) 1974-10-29 1976-12-28 Armour Pharmaceutical Company Pharmaceutical preparations containing 5'-(8'-hydroxyquinolyl)guanidine compounds and methods of using same
KR860002082A (ko) * 1984-08-29 1986-03-26 프랑시스 글로리 자기 변환기 헤드 구조물
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
DK0735877T3 (da) * 1993-12-17 2000-11-06 Procter & Gamble 6-(2-imidazolinylamino)quinoxalinforbindelser, der er egnede som alfa-2-adrenoceptoragonister.
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
DE69732244T2 (de) 1996-11-25 2006-06-29 The Board Of Regents Of The University Of Nebraska, Lincoln Guanidyl-heterocyclische verbindungen als alpha-2 adrenoceptor agonisten
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CN1242006A (zh) 2000-01-19
US6225331B1 (en) 2001-05-01
ZA9710578B (en) 1998-06-25
US20020128481A1 (en) 2002-09-12
IL130077A0 (en) 2000-02-29
KR20000069131A (ko) 2000-11-25
NO313912B1 (no) 2002-12-23
AU5438198A (en) 1998-06-22
EP0944604A1 (en) 1999-09-29
HUP0000312A2 (hu) 2000-09-28
AU730369B2 (en) 2001-03-08
NO992498L (no) 1999-07-26
RU2194700C2 (ru) 2002-12-20
NZ336010A (en) 2001-05-25
CZ184099A3 (cs) 1999-11-17
DE69732244T2 (de) 2006-06-29
CN1104422C (zh) 2003-04-02
NO992498D0 (no) 1999-05-25
JP2001506600A (ja) 2001-05-22
SK69799A3 (en) 2000-06-12
CA2272640A1 (en) 1998-06-04
PE16399A1 (es) 1999-03-12
ATE286885T1 (de) 2005-01-15
CA2272640C (en) 2003-07-08
EP0944604B1 (en) 2005-01-12
BR9713536A (pt) 2000-11-07
ID23857A (id) 2000-05-25
US20010000345A1 (en) 2001-04-19
US6391878B2 (en) 2002-05-21
AR009145A1 (es) 2000-03-08
ES2236833T3 (es) 2005-07-16
DE69732244D1 (de) 2005-02-17
CO4910148A1 (es) 2000-04-24
HUP0000312A3 (en) 2001-12-28
WO1998023596A1 (en) 1998-06-04

Similar Documents

Publication Publication Date Title
TR199901885T2 (tr) Alfa-2 adrenoseptör agonistleri olarak yararli 2-imidazolinilaminoindol bilesikleri.
CA2272640A1 (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
TR199901486T2 (tr) Alfa-2 adrenoseptör agonistleri olarak yararli 2-imidazolinilamino-benzoksazol bilesikleri.
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
SE8503680L (sv) Indolderivat
NO20024521L (no) Heterocyklisk sidekjede-inneholdende metalloproteaseinhibitorer
EA200100623A1 (ru) Кетолидные антибиотики
TR200002971T2 (tr) İkameli pirolidin hidroksamat metaloproteaz inhibitörleri
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
TR200102524T2 (tr) Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
ATE104145T1 (de) 4-substituierten imidazolen zur senkung des intraokularen druckes.
BR0008716A (pt) Inibidores de metaloprotease contendo alquenil ou alquinil
BR0109348A (pt) Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
DK0775118T3 (da) Benzimidazolderivater, der har dopaminerg aktivitet
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
TR199901467T2 (tr) Alfa-2 adrenoseptör agonistleri olarak yararli guanidinilamino heterosikl bilesikleri.
TR199901542T2 (tr) Alfa-2 adrenoseptör agonistleri olarak yararli 2-imidazolinilaminoindazol bilesikleri.
TR200002808T2 (tr) İlaç olarak yararlı C11 oksimil ve hidroksilamino prostaglandinleri